Blar i NTNU Open på forfatter "Scott, Helge"

Viser treff 1-3 av 3

    • Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function 

      Pischke, Søren Erik; Gustavsen, Alice; Orrem, HL; Egge, Kjetil Hagene; Courivaud, Fredric A A; Fontenelle, Hugues; Despont, Alain; Bongoni, Anjan K.; Rieben, Robert; Tønnessen, Tor Inge; Nunn, Miles A.; Scott, Helge; Skulstad, Helge; Barratt-Due, Andreas; Mollnes, Tom Eirik (Journal article; Peer reviewed, 2017)
      Inhibition of complement factor 5 (C5) reduced myocardial infarction in animal studies, while no benefit was found in clinical studies. Due to lack of cross-reactivity of clinically used C5 antibodies, different inhibitors ...

    • Expression of estrogen receptor-α and survival in advanced-stage non-small cell lung cancer 

      Lund-Iversen, Marius; Scott, Helge; Strøm, Erik Heyerdahl; Theiss, Noah; Brustugun, Odd Terje; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)
      Background/Aim: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by ...

    • Mutasjonstesting ved ikke-småcellet lungekreft 

      Brustugun, Odd Terje; Helland, Åslaug; Fjellbirkeland, Lars; Kleinberg, Lilach; Ariansen, Sarah Louise; Jebsen, Peter Wilhelm; Scott, Helge; Dønnem, Tom; Bremnes, Roy M.; Berg, Thomas; Grønberg, Bjørn Henning; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Mangseth, Kjersti; Helgeland, Lars (Peer reviewed; Journal article, 2012)
      BAKGRUNN. Epidermal vekstfaktor-reseptor (EGFR) tyrosinkinasehemmere (EGFR-TKI) er en relativt ny klasse legemidler til behandling av ikke-småcellet lungekreft. Den nasjonale faggruppen for lungekreft, Norsk Lunge Cancer ...